Astellas Inks $1.54 Billion Licensing Deal with Evopoint for ADC Candidate XNW27011 Targeting CLDN18.2

- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...

May 30, 2025 | Friday | News
Avance Clinical Empowers US Biotechs With GlobalReady Program Amid Regulatory Uncertainty at Home

As regulatory uncertainty grows in the United States, US biotechs are increasingly looking to Australia as a stable and predictable launchpad for early-p...

May 27, 2025 | Tuesday | News
Fujirebio Receives FDA Clearance for First Blood-Based Test to Aid Alzheimer’s Diagnosis in the U.S.

Fujirebio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/&beta...

May 19, 2025 | Monday | News
Microba’s MetaXplore™ GI Plus Demonstrates Clinical Impact in Over 70% of Patients With Chronic Gut Symptoms

Microba Life Sciences Limited, a precision microbiome company,  announces preliminary results from the analysis of over 4,600 MetaXplore™ GI P...

May 16, 2025 | Friday | News
Biocom California and KoreaBIO Sign MOU to Strengthen US-Korea Life Science Collaboration

Biocom California, the association representing the California life science industry, and KoreaBIO, a life science trade association which seeks to solid...

May 13, 2025 | Tuesday | News
Conduit Pharmaceuticals Secures Korean Patent for AZD1656, Strengthening Global IP Portfolio for Autoimmune Drug

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectu...

May 12, 2025 | Monday | News
BioAegis Launches Global 600-Patient Phase 2 Trial of rhu-pGSN to Treat ARDS and Advance Inflammation-Modulating Therapies

600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...

May 07, 2025 | Wednesday | News
Australia’s Immutep Achieves 17.6-Month Survival with Chemo-Free Immunotherapy in Head and Neck Cancer

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS...

May 06, 2025 | Tuesday | News
CEO Chris Cargill Marks One-Year Transformation Milestone as Nxera Pharma Reports Strong Q1 2025 Progress

Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...

May 05, 2025 | Monday | Company results
Scorpius Holdings Announces Strategic Update Amid Rising CDMO Demand, Eyes Expansion into Southeast Asia

Scorpius Holdings, Inc. (OTC: SCPX), a biomanufacturing company dedicated to advancing therapeutic production capabilities, today announced a comprehensi...

May 05, 2025 | Monday | News
John Rim Drives Samsung Biologics to KRW 1.3 Trillion Q1 Revenue as Plant 5 and ADC Facility Fuel Global CDMO Expansion

- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...

April 24, 2025 | Thursday | Company results
Precision Medicine in Asia: From Genomics to Oncology Impact

    As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...

April 11, 2025 | Friday | Interview
China’s Telitacicept Sets New Benchmark in gMG Treatment with Landmark Phase 3 Results

Impressive results of the Phase 3 clinical trial (NCT05737160) evaluating the efficacy and safety of Telitacicept (synonym: RC18; brand name: 泰爱®...

April 09, 2025 | Wednesday | News
South Korea Makes History with World’s First Recombinant Anthrax Vaccine Approval

GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly develop...

April 09, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close